loader2
Partner With Us NRI

Company details

67.60
70.40
46.60
83.60
6M Return 11.83%
1Y Return 10.82%
Mkt Cap.(Cr) 50.91
Volume 7,106
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 7,106

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 29.63 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 22,733.13 -38,406.68
LAST 3M 72,017.19 -50,293.88
LAST 6M 138,790.76 -188,500.14
LAST 12M 206,712.84 -177,545.72
  • Announcement
  • Corporate action
  • No Data Found

Date Action Type Ratio
No data found

Information

  • About Company
  • Company Info
  • Listing Info
10.03
56.36%
39.3505
18.12%
19.44%
Description
  • Godavari Drugs is engaged in manufacturing drugs. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand. The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa). The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO. In 2000 the company introduced `Pyrazyamide` in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of `Pyrazyamide` of 180 TPA and have also finalised on other products Cislactum,which is a intermediate used to produce Diltiazem an anti anginal drug.

Read More

Registered Address

Mayfair 1-8-303-34, Sardar Patel Road, Secunderabad, Andhra Pradesh, 500003

Tel : 91-40-27849700/27844557
Email : info:godavaridrugs.com
Website : http://www.godavaridrugs.com

Registrar

CIL Securities Limited

AGM Date (Month) : Aug
Face Value Equity Shares : 10
Market Lot Equity Shares : 1
BSE Code : 530317
NSE Code :
Book Closure Date (Month) : Aug
BSE Group : X
ISIN : INE362C01012

ICICIdirect Godavari Drugs Ltd FAQ

You can buy Godavari Drugs Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Godavari Drugs Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 25, 2022 02:47 PM the closing price of Godavari Drugs Ltd was ₹ 67.60.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 25, 2022 02:47 PM, the market cap of Godavari Drugs Ltd stood at ₹ 50.91.
The latest PE ratio of Godavari Drugs Ltd as of May 25, 2022 02:47 PM is 10.03
The latest PB ratio of Godavari Drugs Ltd as of May 25, 2022 02:47 PM is 0.56
The 52-week high of Godavari Drugs Ltd is ₹ 83.60 while the 52-week low is ₹ 46.60 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE